Biomea Q3 net loss $16.4M (down 50% YoY); cash $47M; advances icovamenib and BMF-650

Biomea Fusion, Inc.

2025-Q3 EPS reported -$1.45 vs consensus -$0.26 ▼ miss (-455.8%)

Net loss $16.4M for Q3 2025 vs $32.8M in Q3 2024; R&D expenses down ~47% YoY.
Cash, cash equivalents $47M as of Sep 30, 2025; raised ~$68M in two public offerings extending runway into Q1 2027.
Icovamenib Phase II COVALENT-111: 1.5% mean HbA1c reduction at Week 52 in severe insulin-deficient T2D patients (p=0.01).
BMF-650 (oral GLP-1 RA) dosed first patient in Phase I; 28-day weight reduction data expected H1 2026.
Workforce reduced to ~40 employees as part of operational streamlining.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.